TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
施金元SHIH, JIN-YUAN
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
41筆
11
Chang, L. K., & Shih, J. Y. (2020). Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2(V659E) Mutation. Jco Precision Oncology, 4, 912-915. https://doi.org/10.1200/po.20.00114
12
Chen, C. Y., Chen, K. Y., Shih, J. Y., & Yu, C. J. (2020). Clinical factors associated with treatment toxicity of pemetrexed plus platinum in elderly patients with non-small cell lung cancer. Journal of the Formosan Medical Association, 119(10), 1506-1513. https://doi.org/10.1016/j.jfma.2019.12.007
13
Hsieh, C. C., Ho, C. C., Lin, Z. Z., Yu, C. J., Jow, G. M., Huang, F. Y., Shih, J. Y., & Hsiao, F. H. (2020). Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life. Psychology & Health. https://doi.org/10.1080/08870446.2020.1825713
14
Lin, C. C., Huang, Y. K., Cho, C. F., Lin, Y. S., Lo, C. C., Kuo, T. T., Tseng, G. C., Cheng, W. C., Chang, W. C., Hsiao, T. H., Lai, L. C., Shih, J. Y., Liu, Y. H., Chao, K. S. C., Hsu, J. L., Lee, P. C., Sun, X., Hung, M. C., & Sher, Y. P. (2020). Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics, 10(24), 10925-10939. https://doi.org/10.7150/thno.49425
15
Lin, Y. T., Tsai, T. H., Wu, S. G., Liu, Y. N., Yu, C. J., & Shih, J. Y. (2020). Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. Lung Cancer, 145, 1-9. https://doi.org/10.1016/j.lungcan.2020.04.022
16
Liu, Y. N., Tsai, M. F., Wu, S. G., Chang, T. H., Tsai, T. H., Gow, C. H., Wang, H. Y., & Shih, J. Y. (2020). miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-kappa B Pathway. Molecular Therapy-Nucleic Acids, 22, 471-483. https://doi.org/10.1016/j.omtn.2020.09.015
17
Lu, H. H., Lin, S. Y., Weng, R. R., Juan, Y. H., Chen, Y. W., Hou, H. H., Hung, Z. C., Oswita, G. A., Huang, Y. J., Guu, S. Y., Khoo, K. H., Shih, J. Y., Yu, C. J., & Tsai, H. C. (2020). Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma. Ebiomedicine, 57, Article 102846. https://doi.org/10.1016/j.ebiom.2020.102846
18
Shih, J. Y., Inoue, A., Cheng, R., Varea, R., & Kim, S. W. (2020). Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. Cancers, 12(9), Article 2658. https://doi.org/10.3390/cancers12092658
19
Wang, H. Y., Liu, Y. N., Wu, S. G., Hsu, C. L., Chang, T. H., Tsai, M. F., Lin, Y. T., & Shih, J. Y. (2020). MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process. Cancer Biomarkers, 28(3), 351-363. https://doi.org/10.3233/cbm-191119
20
Wang, J. Y., Shih, J. Y., & Lin, M. C. (2020). Time to be familiar with nontuberculous mycobacterial lung disease-An emerging disease with diverse clinical outcomes. Journal of the Formosan Medical Association, 119, S1-S3. https://doi.org/10.1016/j.jfma.2020.06.018
